Ashland
ASH

$85.01

1.46%

Market Cap: $4.15B

About: Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. Ashland includes only U.S. and Canada in its North America designation and includes Europe, the Middle East and Africa in its Europe designation.

Employees: 3,800

Materials Chemicals & Allied Products, Wholesale

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

33% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 8 (+2) [Q2]

30% more call options, than puts

Call options by funds: $5.14M | Put options by funds: $3.94M

14% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 42

11% more repeat investments, than reductions

Existing positions increased: 131 | Existing positions reduced: 118

2% more funds holding

Funds holding: 369 [Q1] → 375 (+6) [Q2]

2.11% less ownership

Funds ownership: 93.41% [Q1] → 91.29% (-2.11%) [Q2]

5% less capital invested

Capital invested by funds: $4.56B [Q1] → $4.31B (-$246M) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$89

5%

upside

Avg. target

$97

14%

upside

High target

$107

26%

upside

4 analyst ratings

2 positive

50%

2 neutral

50%

0 negative

0%

UBS Joshua Spector 46% 1-year accuracy 17 / 37 met price target	26%upside $107	Buy Maintained	15 Aug 2024
BMO Capital John McNulty 63% 1-year accuracy 24 / 38 met price target	8%upside $92	Market Perform Maintained	9 Aug 2024
Wells Fargo Michael Sison 44% 1-year accuracy 14 / 32 met price target	18%upside $100	Overweight Maintained	8 Aug 2024
JP Morgan Jeffrey Zekauskas 76% 1-year accuracy 25 / 33 met price target	5%upside $89	Neutral Upgraded	8 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about ASH published over the past 30 days

Zacks Investment Research

Ashland Wraps Up Nutraceuticals Business Sale to Turnspire Affiliate

ASH's nutraceuticals business provides nutrition product producers with a diverse selection of active ingredients and formulation aids.

Ashland Wraps Up Nutraceuticals Business Sale to Turnspire Affiliate

Pharmachem Innovations Launches as a Leading Independent Provider of Nutraceuticals Products and Solutions

KEARNY, N.J.--(BUSINESS WIRE)--Pharmachem Innovations, LLC (“Pharmachem” or the “Company”), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE: ASH) by Turnspire Capital Partners LLC (“Turnspire”). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuti.

Pharmachem Innovations Launches as a Leading Independent Provider of Nutraceuticals Products and Solutions

Turnspire Capital Partners Completes Acquisition of Pharmachem from Ashland

NEW YORK--(BUSINESS WIRE)--Turnspire Capital Partners LLC (“Turnspire”) announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC (“Pharmachem” or the “Company”), the former nutraceuticals business of Ashland Inc. (NYSE: ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition.

Turnspire Capital Partners Completes Acquisition of Pharmachem from Ashland

Ashland completes sale of nutraceuticals business

WILMINGTON, Del., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced it has completed the sale of its nutraceuticals business to an affiliate of Turnspire Capital Partners LLC (“Turnspire”) effective August 30, 2024. The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.

Ashland completes sale of nutraceuticals business

Zacks Investment Research

Here's Why Ashland (ASH) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Ashland (ASH) is a Strong Value Stock

Ashland board authorizes quarterly dividend

WILMINGTON, Del., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on September 15, 2024, to stockholders of record at the close of business on September 1, 2024.

Ashland board authorizes quarterly dividend

Zacks Investment Research

ASH vs. NVZMY: Which Stock Should Value Investors Buy Now?

Investors with an interest in Chemical - Specialty stocks have likely encountered both Ashland (ASH) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

ASH vs. NVZMY: Which Stock Should Value Investors Buy Now?

Ashland Inc. (ASH) Q3 2024 Earnings Call Transcript

Ashland Inc. (NYSE:ASH ) Q3 2024 Earnings Conference Call August 7, 2024 10:00 AM ET Company Participants William Whitaker - Vice President-Finance and Director-Investor Relations Guillermo Novo - Chair of the Board and Chief Executive Officer Kevin Willis - Senior Vice President and Chief Financial Officer Conference Call Participants Christopher Parkinson - Wolfe Research John McNulty - BMO Capital Markets David Begleiter - Deutsche Bank Michael Sison - Wells Fargo Mike Harrison - Seaport Research Partners Jeff Zekauskas - JPMorgan John Roberts - Mizuho Joshua Spector - UBS Operator Good day and thank you for standing by. Welcome to the Ashland Inc. Third Quarter 2024 Earnings Conference Call.

Ashland Inc. (ASH) Q3 2024 Earnings Call Transcript

Zacks Investment Research

Why Ashland (ASH) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Ashland (ASH) is a Top Value Stock for the Long-Term

Zacks Investment Research

Ashland's (ASH) Earnings Beat Estimates in Q3, Sales Lag

Ashland's (ASH) Q3 sales are adversely impacted by reduced Life Sciences volumes and weaker pricing.

Ashland's (ASH) Earnings Beat Estimates in Q3, Sales Lag

See News Rankings